ResMed (RMD) continues to instil investor confidence as a guaranteed spot on their watchlist, largely owing to its potential intrinsic value, which is reportedly 47% above its current share price. ResMed's first fabric mask enhancement to its CPAP Therapy and positive third quarter earnings, despite freight cost pressure, further underline its growth. Its
Q4 earnings outperformed previous estimates, leading to stock performance surpassing underlying earnings growth over the last five years. ResMed's adherence to its 2030 strategy, institutional investment footprint, and recent stock purchases made by insiders reaffirm its strong financial prospects. However, the company recently faced a blow, with its stocks tumbling by 5% due to potential threats from weight-loss drugs. Despite this, ResMed retained profits, meeting estimates for 2024's Q4. It also announced its intention to unveil the AirCurve 11 Device for sleep apnea and projected steady revenue despite possible market disruption challenges. ResMed's robust growth trajectory is further validated by the increase in stock holdings by large entities, such as Handelsbanken Fonder AB, and by favourable price targets set by financial analysts.
Resmed RMD News Analytics from Mon, 01 Apr 2024 07:00:00 GMT to Sat, 12 Oct 2024 00:48:57 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor 2
